本報告已在2011年07月19日停止出版。
Abstract
Interest in and use of the technology has exploded in recent years, thanks to advances in cell biology, biochemical agents, and computer analysis. Research groups around the world are joining the effort to use magnetic, nuclear, and optical imaging techniques to study the molecular interactions that underlie biological processes.
This market briefing presents an overview of the market for molecular imaging agents and systems. The briefing provides an introduction to molecular imaging modalities and applications, and focuses on imaging agents that are in clinical trials, or that are recently introduced commercial products. Market analysis and forecasts are developed through 2009 and profiles.
Table of Contents
Chapter One: Executive Summary
- Scope
- Revolution in Disease Treatment
- Market Summary
- The Pipeline
Chapter two: Introduction
- Definitions
- Molecular Imaging
- Molecular Imaging Agents
- Imaging Modalities
- Nuclear Pharmaceuticals
- MI Agent Research
- Collaborations and Synergy Needed
chapter three: Promising Technologies and
- Applications
- Overview
- SPECT
- Alzheimers Disease
- Serotonin Reuptake Inhibitor
- Folate Receptor-Positive Cancers
- Computed Tomography
- Imaging Cell Death
- Bone Evaluation
- Imaging Critical Blood Flow
- Super Paramagnetic Agents
- Metastatic Lymph Nodes
- Iron Oxide Nanoparticles
- Microbubbles
- Gene Expression
- Strategies for Cancer
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Latent Heart Disease
- The Source of Infection
Chapter Four: Research and Development Methodology and Strategies
Chapter Five: Market Analysis
- Market Size and Growth
- Movement into the Radiology Laboratory
- Evaluating Treatment Efficacy
- SPECT and Gamma Cameras
- New Market for Gamma Cameras
- New Market Opportunities
- Significant Market for Alzheimers Disease
- The Impact of Ultrasound Imaging Agents
- Competitive Landscape
- Market Drivers
- Aging Population Drives Imaging Utilization
- Increased Functionality of Products
- Need for Digitization
- Novel Contrast Agents
- Market Restraints
- Maturity Limits Opportunities
- Rapid Pace of Innovation Restricts Spending
- Market Consolidation
Chapter Six: Company Profiles
- Advanced Magnetics
- Alerion Biomedical
- AnorMED
- Boston Life Sciences
- Cytogen
- Epix Pharmaceuticals
- Mallinckrodt
Appendix: References
list of exhibits
Chapter One: Executive Summary
- Exhibit 1: Market Summary: Sales of Imaging Agents* United States and World 2003-2009
- Exhibit 2: Market Summary: U.S. Sales of Molecular Imaging Equipment by Modality 2004-2009
Chapter two: Introduction
- Exhibit 3: Representative Molecular Imaging Agents in Common Use
- Exhibit 4: In Vivo Molecular Imaging Modalities and Their Approximate Sensitivities
- Exhibit 5: Table of Common Radionuclides
- Exhibit 6: Selected Examples of Contrast Media and Complimentary Imaging Modalities
Chapter Five: Market Analysis
- Exhibit 7: U.S. Sales of Molecular Imaging Equipment by Modality (Ultrasound, SPECT & SPECT/CT Combinations, MRI, and PET & PET/CT Combinations) 2004-2009
- Exhibit 8: U.S. and Worldwide Sales of Imaging Agents 2003-2009
- Exhibit 9: Molecular Imaging Agents Currently Available for Magnetic Resonance and Ultrasound (Manufacturer, Agent Name, and Modality)
- Exhibit 10: Estimated Potential Peak Yearly U.S Usage for Selected New Imaging Agents (Manufacturer, Product, Use, Peak Procedure Estimate)
- Exhibit 11: Number of U.S Imaging Procedures by Modality 2003-2009
- Exhibit 12: U.S Gamma Camera Market Shipments and Installed Base 2004
